Seers Technology (hereinafter Seers) is accelerating the introduction of artificial intelligence (AI) testing in the 5 trillion KRW health screening market. The company plans to target 22.86 million examinees by securing top-tier health screening centers in Korea as clients.
On the 17th, Seers announced that it will supply the 'AI Electrocardiogram (ECG) Testing Solution' using 'MobiCare' to the Korea Association of Health Promotion (Medichek, hereinafter KAH) through Daewoong Pharmaceutical.
KAH is the top health screening specialized institution in Korea, consisting of 17 branches nationwide. Starting this month, sequentially across its 17 branches, KAH plans to launch an AI ECG testing service specialized in cardiovascular disease, particularly arrhythmia screening, using MobiCare.
ECG testing is used for the prevention and diagnosis of heart diseases, which are the leading cause of death worldwide. The traditional testing method involved analyzing the heart’s electrical activity by a physician. However, due to a shortage of ECG specialists and the high costs of ECG devices and interpretation software, testing was only available at some large hospitals. Additionally, patients often hesitated to undergo testing because the devices were heavy and uncomfortable to wear.
Seers’ MobiCare lowers the barrier to ECG testing by enabling examinations at general hospitals through the use of wearable ECG devices and AI algorithms. It has been recognized by the Health Insurance Review & Assessment Service as a reimbursable medical service under the National Health Insurance system, allowing hospitals and patients to benefit from insurance coverage. This has created an environment that satisfies both hospitals and patients.
Seers has broadened its focus to popularize 'ECG testing' in general health screenings. Since 2021, it has conducted clinical trials for arrhythmia screening on 3,000 health screening examinees at six university hospitals, including Seoul National University Hospital, demonstrating the clinical efficacy of arrhythmia screening for asymptomatic general populations.
Examinees at KAH can choose between same-day screening or one-day screening. Those who select same-day screening attach the MobiCare device upon entering the screening center and return the device upon leaving. Those who choose one-day screening wear the device home and return it via a dedicated courier service provided by Seers after the 24-hour measurement period ends. The examinees’ ECG data are initially analyzed by AI, and diagnostic reports including expert review by arrhythmia specialists are provided to the examinees.
A company representative stated, "There are over 5 million hypertensive patients aged 65 and older, for whom early prevention of acute heart disease is essential. As awareness of heart disease increases, we expect the number of examinees seeking early screening services using MobiCare to continue growing."
With the acquisition of top-tier large health screening centers as clients, Seers’ performance growth is also anticipated. Seers is smoothly expanding its customer base not only to specialized screening centers but also to university hospital screening centers and overseas screening centers, suggesting rapid growth in revenue scale in the future.
The representative added, "This year, we plan to focus on stabilizing services at specialized screening centers with large numbers of examinees. From next year, when the service is fully launched, a stable revenue base is expected to be secured."
Seers is also pursuing pipeline expansion for MobiCare. The company is currently verifying AI solutions using ECG data for predicting atrial fibrillation, heart failure, hyperkalemia, and diagnosing mental disorders through clinical trials. After field validation, these are expected to be included as new testing items in the health screening market.
The domestic health screening market size is estimated at approximately 5 trillion KRW. According to the Health Screening Statistical Yearbook, as of 2022, the target population for health screening was 22.86 million, of which 17.23 million underwent screening.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
